Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年9月11日
	新闻
	Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab American Journal of Managed Care The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years. 标记为不相关
	No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in ... The ASCO Post Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈